Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 207 participants.

Also called NCT02725372

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 207 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02725372
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Canada, Colombia, Croatia, Czechia, France, Germany, Israel, Italy, Netherlands, Portugal, Serbia, Spain, Ukraine, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02725372. Randomized; quadruple masking; primary purpose treatment. Start 2016-04 (actual); primary completion 2018-08 (actual). Results posted on 2023-01-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Acronym
INOvation-1
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Inhaled Nitric Oxide 75 mcg/kg IBW/hr
Intervention (Drug)
Placebo
Lead sponsor
Bellerophon Pulse Technologies (class: industry)
Collaborator
Worldwide Clinical Trials (class: other)

Record details

Record id
cardio:ct-nct02725372
Content hash
11df83d5d9bd51347dc14ad5ddf1aabbb277e771483302bab1986da9cc1dfbae